Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
- Initiation of the first German study center planned within the next few months
Heidelberg Pharma AG today announced that the German authority Paul Ehrlich Institute, Langen, Germany, (PEI) has approved the study design of the planned Phase I/IIa clinical trial with the ATAC candidate HDP-101. HDP-101 is a BCMA antibody-Amanitin conjugate that will be tested in the indication multiple myeloma, a blood cancer with high unmet medical need.